Key result
Decellularized aortic homografts demonstrate ~2% mortality and low gradients at 2.5 years.
Why the study?
Conventional allogenic and xenogenic aortic valve prostheses have a high early failure rate in young patients, and non-cryopreserved decellularized aortic homografts may provide an additional aortic valve replacement option to overcome this limitation.
Does aortic valve replacement with decellularized aortic homografts provide safe periprocedural outcomes and favourable early haemodynamic function in paediatric and young adult patients requiring aortic valve replacement?
Cohort (n=144)
Open-label
Yes
Does aortic valve replacement with decellularized aortic homografts provide safe periprocedural outcomes and favourable early haemodynamic function in paediatric and young adult patients requiring aortic valve replacement?
Decellularized aortic homografts demonstrate low early mortality and excellent short-term haemodynamic performance comparable to the Ross procedure, offering a promising biological aortic valve replacement alternative for young patients.
Answers are grounded in this paper and cite their sources.
Early results support further evaluation of decellularized homografts in young patients; randomized trials needed to confirm durability versus alternatives.
OBJECTIVES: Decellularized aortic homografts (DAH) may provide an additional aortic valve replacement option for young patients due to their potential to overcome the high early failure rate of conventional allogenic and xenogenic aortic valve prostheses. METHODS: A prospective, European Union-funded, single-arm, multicentre, safety study was conducted in 8 centres evaluating non-cryopreserved DAH for aortic valve replacement. RESULTS: One hundred and forty-four patients (99 male) were prospectively enrolled between October 2015 and October 2018, mean age 33.6 ± 20.8 years; 45% had undergone previous cardiac operations. Mean implanted DAH diameter 22.6 ± 2.4 mm and mean durations for the operation, cardiopulmonary bypass and cross-clamp were 341 ± 140, 174 ± 80 and 126 ± 43 min, respectively. There were 2 early deaths (1 LCA thrombus on day 3 and 1 ventricular arrhythmia 5 h postop) and 1 late death due to endocarditis 4 months postoperatively, resulting in a total mortality of 2.08%. One pacemaker implantation was necessary and 1 DAH was successfully repaired after 6 weeks for early regurgitation following subcoronary implantation. All other DAH were implanted as a free-standing root. After a mean follow-up of 1.54 ± 0.81 years, the primary efficacy end points peak gradient (mean 11.8 ± 7.5 mmHg) and regurgitation (mean 0.42 ± 0.49, grade 0-3) were excellent. At 2.5 years, freedom from explantation/endocarditis/bleeding/stroke was 98.4 ± 1.1%/99.4 ± 0.6%/99.1 ± 0.9%/99.2 ± 0.8%, respectively, with results almost identical to those in an age-matched Ross operation cohort of 212 patients (mean age 34 years) despite DAH patients having undergone >2× more previous procedures. CONCLUSIONS: The initial results of the prospective multicentre ARISE trial show DAH to be safe for aortic valve replacement with excellent haemodynamics in the short follow-up period.
No takes yet. Share an insight, caveat, or question.
Horke et al. (2020) conducted a cohort in Valvular heart disease requiring aortic valve replacement (n=144). Decellularized aortic homograft (DAH, Arise AV) vs. Historical cohorts (age-matched Ross operation cohort and published meta-analyses of Ross, mechanical, and bioprosthetic valves) was evaluated on Primary efficacy endpoints of mean peak aortic gradient (mmHg) and regurgitation (grade 0-3), alongside total mortality (%). Decellularized aortic homografts yielded 2.08% total mortality, mean peak gradient of 11.8±7.5 mmHg, and 98.4% freedom from explantation at 2.5 years.
Synapse has enriched 10 related papers. Consider them for comparative context: